Format

Send to

Choose Destination
Front Pharmacol. 2014 Mar 20;5:44. doi: 10.3389/fphar.2014.00044. eCollection 2014.

Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms.

Author information

1
Central European Institute of Technology, Masaryk University Brno, Czech Republic ; Department of Pharmacology, Faculty of Medicine, Masaryk University Brno, Czech Republic.
2
Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari Monserrato, Italy.
3
Institute of Biostatistics and Analyses of Faculty of Medicine, Masaryk University Brno, Czech Republic.
4
Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari Monserrato, Italy ; Center of Excellence "Neurobiology of Addiction," University of Cagliari Monserrato, Italy ; National Institute of Neuroscience (INN), University of Cagliari Monserrato, Italy.
5
Central European Institute of Technology, Masaryk University Brno, Czech Republic.
6
Center of Excellence "Neurobiology of Addiction," University of Cagliari Monserrato, Italy ; CNR Institute of Neuroscience-Cagliari, National Research Council-Italy Monserrato, Italy.

Abstract

Depression has been associated with drug consumption, including heavy or problematic cannabis use. According to an animal model of depression and substance use disorder comorbidity, we combined the olfactory bulbectomy (OBX) model of depression with intravenous drug self-administration procedure to verify whether depressive-like rats displayed altered voluntary intake of the CB1 receptor agonist WIN55,212-2 (WIN, 12.5 μg/kg/infusion). To this aim, olfactory-bulbectomized (OBX) and sham-operated (SHAM) Lister Hooded rats were allowed to self-administer WIN by lever-pressing under a continuous [fixed ratio 1 (FR-1)] schedule of reinforcement in 2 h daily sessions. Data showed that both OBX and SHAM rats developed stable WIN intake; yet, responses in OBX were constantly higher than in SHAM rats soon after the first week of training. In addition, OBX rats took significantly longer to extinguish the drug-seeking behavior after vehicle substitution. Acute pre-treatment with serotonin 5HT1B receptor agonist, CGS-12066B (2.5-10 mg/kg), did not significantly modify WIN intake in OBX and SHAM Lister Hooded rats. Furthermore, acute pre-treatment with CGS-12066B (10 and 15 mg/kg) did not alter responses in parallel groups of OBX and SHAM Sprague Dawley rats self-administering methamphetamine under higher (FR-2) reinforcement schedule with nose-poking as operandum. Finally, dopamine levels in the nucleus accumbens (NAc) of OBX rats did not increase in response to a WIN challenge, as in SHAM rats, indicating a dopaminergic dysfunction in bulbectomized rats. Altogether, our findings suggest that a depressive-like state may alter cannabinoid CB1 receptor agonist-induced brain reward function and that a dopaminergic rather than a 5-HT1B mechanism is likely to underlie enhanced WIN self-administration in OBX rats.

KEYWORDS:

WIN55212-2; cannabinoid; depression; dopamine; drug dependence; methamphetamine; olfactory bulbectomy; serotonin

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center